VolitionRx (NYSE:VNRX) Earns Sell Rating from Analysts at StockNews.com

Analysts at StockNews.com started coverage on shares of VolitionRx (NYSE:VNRX) in a research report issued to clients and investors on Saturday. The brokerage set a “sell” rating on the stock.

Separately, D. Boral Capital reaffirmed a “buy” rating and issued a $5.00 price target on shares of VolitionRx in a report on Monday, March 31st.

VolitionRx Stock Performance

VNRX stock opened at $0.53 on Friday. The firm has a 50-day simple moving average of $0.58 and a two-hundred day simple moving average of $0.63. VolitionRx has a one year low of $0.43 and a one year high of $1.02. The firm has a market cap of $49.33 million, a price-to-earnings ratio of -1.48 and a beta of 1.09.

Insider Buying and Selling at VolitionRx

In related news, CEO Cameron John Reynolds bought 181,818 shares of the company’s stock in a transaction that occurred on Wednesday, March 26th. The shares were purchased at an average cost of $0.55 per share, with a total value of $99,999.90. Following the completion of the acquisition, the chief executive officer now directly owns 2,299,222 shares in the company, valued at approximately $1,264,572.10. The trade was a 8.59 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 12.80% of the company’s stock.

Hedge Funds Weigh In On VolitionRx

A number of hedge funds have recently bought and sold shares of VNRX. Lagoda Investment Management L.P. lifted its position in shares of VolitionRx by 24.3% during the 4th quarter. Lagoda Investment Management L.P. now owns 7,576,000 shares of the company’s stock valued at $4,546,000 after buying an additional 1,481,000 shares in the last quarter. Geode Capital Management LLC raised its position in VolitionRx by 15.1% during the third quarter. Geode Capital Management LLC now owns 730,448 shares of the company’s stock worth $439,000 after acquiring an additional 95,900 shares during the period. Millennium Management LLC purchased a new position in VolitionRx during the fourth quarter valued at $36,000. Two Sigma Securities LLC purchased a new position in VolitionRx during the fourth quarter valued at $29,000. Finally, Northern Trust Corp increased its stake in shares of VolitionRx by 32.0% during the fourth quarter. Northern Trust Corp now owns 117,875 shares of the company’s stock worth $71,000 after purchasing an additional 28,579 shares in the last quarter. Hedge funds and other institutional investors own 8.09% of the company’s stock.

VolitionRx Company Profile

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.